Oncology

The chief of research and immunotherapy at Cedars-Sinai The Angeles Clinic and Research Institute discussed updated data from the phase 2 C-144-01 study of the lifileucel TIL therapy.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

A2B530 and A2B694 target CEA and MSLN cells that have HLA loss of heterozygosity.

Among the 16 patients treated in the trial, 5 showed stable disease after treatment.

Review top news and interview highlights from the week ending November 11, 2022.

Data from the COBALT-RCC study in renal cell carcinoma were presented at SITC 2022.

The data included an IRC-assessed ORR of 31.4%.

The patient’s ECOG performance status remained at 0 from screening through the rest of trial participation.

The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.

Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

The chair of gynecologic oncology at Moffitt Cancer Center gave an overview of a phase 1 trial being conducted at Moffitt Cancer Center.

Review top news and interview highlights from the week ending November 4, 2022.

Data from the first 2 patients were presented at the IWWM 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chair of gynecologic oncology at Moffitt Cancer Center discussed advantages of targeting follicle stimulating hormone receptor with cell therapy for ovarian cancer.

MT-101 is designed for quick delivery to patients with a vein-to-vein time of 8 days.

The medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.

Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.

TIDAL-01 will be evaluated in patients with advanced or metastatic breast carcinoma, colorectal adenocarcinoma, or uveal melanoma.

Cellular Biomedicine group developed the therapy after efficacy was seen with Iovance’s lifilecuel in solid tumor studies.

Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.

Shah explained that the trial is unique due to its inclusion of patients with MRD–positive B-ALL.

The chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.

RZ-001 previously received IND clearance from the South Korean Ministry of Food and Drug Safety in June.

The decision comes after strategic uncertainty regarding a review of preliminary clinical data from GSK’s lete-cel product candidate trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Cells produced by this method were also shown to be more potent in animal models than cells made with typical processes.